Elevation Oncology Accelerates Cancer Treatment Innovations with EO-1022, a New ADC Development Candidate

Elevation Oncology Expands Its Pipeline with EO-1022

Elevation Oncology, Inc., a forward-thinking oncology firm traded on Nasdaq under the symbol ELEV, has made significant strides by naming EO-1022 as its latest antibody-drug conjugate (ADC) candidate developed specifically for HER3-expressing solid tumors. As this innovative company focuses on the discovery of precise cancer treatments, the nomination of EO-1022 stands out as a pivotal advancement in their ongoing efforts to tackle various solid tumors characterized by pronounced unmet medical needs.

The Significance of EO-1022

The foundation of EO-1022 lies in seribantumab, an anti-HER3 monoclonal antibody, which is skillfully combined with a monomethyl auristatin E (MMAE) payload. The unique site-specific conjugation allows for targeted delivery, aiming to enhance the therapeutic impact on cancer cells expressing HER3. By leveraging cutting-edge technology, EO-1022 is positioned to make a substantial difference in treatment approaches for cancers such as breast cancer, EGFR-mutant non-small cell lung cancer, and pancreatic cancer, all of which are notoriously challenging to treat.

Joseph Ferra, President and Chief Executive Officer of Elevation Oncology, expressed enthusiasm about this development. "The nomination of our HER3-ADC candidate is an important milestone which reinforces our ADC pipeline. Combining seribantumab with advanced ADC technologies enables us to deliver a cytotoxic payload directly to HER3-overexpressing cells,” he stated. He also highlighted that seribantumab's selectivity and favorable safety profile, established in multiple studies involving over 900 patients, underpin the decision to advance EO-1022.

The Path Ahead

Elevation Oncology is presently advancing EO-1022 through preclinical testing, with plans to file an Investigational New Drug (IND) application in 2026. Initial preclinical data is expected to be shared in the first half of 2025, reflecting the company's commitment to transparency and collaboration within the medical and scientific communities.

To further bolster its ADC development capabilities, Elevation Oncology has entered into a global licensing agreement with Synaffix B.V. This partnership grants Elevation innovative access to Synaffix’s site-specific ADC technology platform, which includes GlycoConnect® for antibody conjugation and HydraSpace® for enhanced solubility. Notably, these technologies promise to enhance the efficacy of EO-1022 by allowing for more precise targeting of HER3, thus opening up new avenues in cancer treatment.

"HER3 presents a compelling target in the battle against various cancer types. An ADC approach promises to epitomize the clinical potential of HER3 therapies," remarked David Dornan, Ph.D., Chief Scientific Officer at Elevation Oncology. The excitement surrounding EO-1022 resides in its potential to shift treatment paradigms for patients with HER3-overexpressing tumors.

About the Companies

Elevation Oncology is on a mission to innovate cancer treatment by focusing on selectively developed therapies aimed at addressing the pressing needs related to solid tumors. Their pipeline extends to two clinically validated targets, including Claudin 18.2, with EO-3021 identified as a potential leading candidate.

Synaffix B.V., the other half of this dynamic partnership, specializes in ADC technologies that facilitate the swift development of proprietary, high-quality ADC products. By allowing companies to leverage their technological expertise under a single license, Synaffix has carved a niche for itself in the biotechnology industry, ensuring accelerated timelines for clinical applications.

As Elevation Oncology pushes forward with EO-1022 and its ambitious pipeline, the development of advanced, selective cancer therapies continues to be at the forefront of the company's mission. With the collaboration between innovative biotech philosophies and cutting-edge technologies, a brighter future for cancer treatment is on the horizon.

For more information and updates on Elevation Oncology’s progress, visit ElevationOncology.com.